Close Menu

NEW YORK – MDxHealth announced Monday that private equity firm MVM Partners has agreed to provide an equity investment of €12.7 million ($13.8 million) to the company.

MVM Partners will receive a subscription of nearly 20.2 million ordinary shares of MDxHealth at an issue price of €0.63 per share, a 5 percent discount to the 45-day volume weighted average price. MVM will become a 22 percent shareholder of the company after the transaction, which is expected to close on or around May 15. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.